USA - NASDAQ:TLPH - US00444T2096 - Common Stock
The current stock price of TLPH is 0.885 USD. In the past month the price increased by 68.21%. In the past year, price increased by 16.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 47.03 | 718.92B | ||
JNJ | JOHNSON & JOHNSON | 18.54 | 446.58B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.45 | 247.55B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.05 | 244.66B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.26 | 237.54B | ||
MRK | MERCK & CO. INC. | 10.86 | 208.81B | ||
PFE | PFIZER INC | 7.48 | 144.10B | ||
SNY | SANOFI-ADR | 10.56 | 114.66B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.75 | 92.44B | ||
GSK | GSK PLC-SPON ADR | 9.57 | 86.79B | ||
ZTS | ZOETIS INC | 23.55 | 64.92B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.41 | 46.17B |
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
TALPHERA INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA US
Employees: 13
Phone: 16502163500
The current stock price of TLPH is 0.885 USD. The price decreased by -2.75% in the last trading session.
The exchange symbol of TALPHERA INC is TLPH and it is listed on the Nasdaq exchange.
TLPH stock is listed on the Nasdaq exchange.
9 analysts have analysed TLPH and the average price target is 4.25 USD. This implies a price increase of 380.23% is expected in the next year compared to the current price of 0.885. Check the TALPHERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TALPHERA INC (TLPH) has a market capitalization of 40.32M USD. This makes TLPH a Nano Cap stock.
TALPHERA INC (TLPH) currently has 13 employees.
TALPHERA INC (TLPH) has a support level at 0.84 and a resistance level at 0.92. Check the full technical report for a detailed analysis of TLPH support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TLPH does not pay a dividend.
TALPHERA INC (TLPH) will report earnings on 2025-11-04.
TALPHERA INC (TLPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
The outstanding short interest for TALPHERA INC (TLPH) is 2.45% of its float. Check the ownership tab for more information on the TLPH short interest.
ChartMill assigns a technical rating of 9 / 10 to TLPH. When comparing the yearly performance of all stocks, TLPH is one of the better performing stocks in the market, outperforming 93.05% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TLPH. The financial health of TLPH is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 37.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -68.45% | ||
ROE | -170.59% | ||
Debt/Equity | 0 |
9 analysts have analysed TLPH and the average price target is 4.25 USD. This implies a price increase of 380.23% is expected in the next year compared to the current price of 0.885.